Roche has revealed plans to invest over SFr 240 million (approximately US$258 million) in its Penzberg biotechnology centre, near Munich, Germany. This further investment in the Penzberg site is a response to sustained global demand for the reagents used in immunoassay testing in laboratories and hospitals.
The plans call for construction of a new production facility, to be known as Diagnostics Operations Complex II (DOCII). The facility is scheduled to be operational in December 2014 and will create 50 new jobs. DOCII will expand production capacity for diagnostic test and control reagents. The facility will have a total floor area of 26,000 sqm and consist of three structures: a central, six-storey laboratory building with a basement level and two adjacent single-level plant buildings.